1. Home
  2. CYH vs PRTC Comparison

CYH vs PRTC Comparison

Compare CYH & PRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Community Health Systems Inc.

CYH

Community Health Systems Inc.

HOLD

Current Price

$2.97

Market Cap

432.2M

Sector

Health Care

ML Signal

HOLD

Logo PureTech Health plc

PRTC

PureTech Health plc

HOLD

Current Price

$15.00

Market Cap

464.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CYH
PRTC
Founded
1985
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Hospital/Nursing Management
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
432.2M
464.3M
IPO Year
2000
N/A

Fundamental Metrics

Financial Performance
Metric
CYH
PRTC
Price
$2.97
$15.00
Analyst Decision
Hold
Analyst Count
7
0
Target Price
$3.57
N/A
AVG Volume (30 Days)
1.3M
3.8K
Earning Date
04-22-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
196.67
N/A
EPS
3.77
N/A
Revenue
$12,485,000,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$2.17
N/A
P/E Ratio
$0.78
$8.09
Revenue Growth
N/A
N/A
52 Week Low
$2.24
$13.30
52 Week High
$4.43
$20.00

Technical Indicators

Market Signals
Indicator
CYH
PRTC
Relative Strength Index (RSI) 42.67 34.78
Support Level $2.94 $14.50
Resistance Level $3.25 $17.98
Average True Range (ATR) 0.12 0.37
MACD -0.01 -0.12
Stochastic Oscillator 35.11 20.24

Price Performance

Historical Comparison
CYH
PRTC

About CYH Community Health Systems Inc.

Community Health Systems Inc is a publicly owned hospital operator in the United States. The company also owns four home health agencies and provides management and consulting services to independent hospitals. The firm derives revenue through a broad range of general and specialized hospital healthcare services and outpatient services.

About PRTC PureTech Health plc

PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.

Share on Social Networks: